Skip to main content
Premium Trial:

Request an Annual Quote

Shimadzu Obtains ISO 13485 Certification for US LC-MS Manufacturing Facility

Premium

Shimadzu said this week that its US manufacturing subsidiary Shimadzu USA Manufacturing has obtained ISO 13485 certification for the manufacture of its liquid chromatography and mass spectrometry systems.

The certification allows SUM to manufacture these instruments for clinical testing in the US market.

"Mass spectrometry has a growing presence in clinical research and laboratory medicine," Shinichi Matsunaga, president of Shimadzu U.S.A. Manufacturing, said in a statement. "Achieving ISO 13485 certification is a major milestone for Shimadzu and a great step towards developing mass spectrometry platforms as next generation medical devices."

The company added that it will continue to registed medical devices with the US Food and Drug Administration, "and support the growing demand for LC and LC-MS in the clinical testing market."

To date, Shimadzu has not registered any of its LC-MS systems with FDA as class I exempt medical devices, a requirement for their use in clinical applications.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.